Profiel
Andrew C.
Lam is the founder of Endurance Bio, Inc. Mr. Lam is Vice President-Product Development at Armetheon, Inc. Mr. Lam was Senior Director-Liquid OROS Technology Development at ALZA Corp., Executive Director-Formulation Development at Exelixis, Inc., and Executive Director-Product Development at Altheos, Inc. Mr. Lam completed undergraduate studies at the University of California, Davis.
Actieve functies van Andrew C. Lam
| Bedrijven | Functie | Begin |
|---|---|---|
Armetheon, Inc.
Armetheon, Inc. Pharmaceuticals: MajorHealth Technology Operates as a cardiovascular focused late-clinical stage specialty pharmaceutical company | Corporate Officer/Principal | - |
Eerdere bekende functies van Andrew C. Lam
| Bedrijven | Functie | Einde |
|---|---|---|
| EXELIXIS, INC. | Corporate Officer/Principal | - |
| ALZA CORPORATION | Corporate Officer/Principal | - |
Altheos, Inc.
Altheos, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Corporate Officer/Principal | - |
Opleiding van Andrew C. Lam
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 5 |
|---|---|
ALZA Corp.
ALZA Corp. Pharmaceuticals: MajorHealth Technology Provides and develops pharmaceutical products | Health Technology |
Exelixis, Inc.
Exelixis, Inc. Pharmaceuticals: MajorHealth Technology Operates as a cancer drug discovery company | Health Technology |
University of California, Davis
University of California, Davis Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Altheos, Inc.
Altheos, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Armetheon, Inc.
Armetheon, Inc. Pharmaceuticals: MajorHealth Technology Operates as a cardiovascular focused late-clinical stage specialty pharmaceutical company | Health Technology |
















